Edition:
United States

Sanofi SA (SNY)

SNY on New York Consolidated

40.40USD
9 Dec 2016
Change (% chg)

$0.63 (+1.58%)
Prev Close
$39.77
Open
$40.21
Day's High
$40.54
Day's Low
$40.17
Volume
1,438,696
Avg. Vol
2,336,237
52-wk High
$44.50
52-wk Low
$36.81

Select another date:

Thu, Dec 8 2016

Photo

EU regulator accepts Sanofi/Regeneron's Dupixent product for review

PARIS The European Medicines Agency (EMA), the European Union's health regulator, has accepted for review the Dupixent product being developed by drugmakers Sanofi and Regeneron, the companies said on Thursday.

Sanofi exploring bid for Actelion amid J&J talks: Bloomberg

French drugmaker Sanofi is considering a bid for Swiss biotech company Actelion , rivaling an offer made by U.S. healthcare company Johnson & Johnson , Bloomberg reported.

Novo, Sanofi go head to head as FDA clears new diabetes drugs

Rivals Novo Nordisk and Sanofi have won U.S. approval for new combination drugs to treat diabetes, sparking a fresh battle for sales in a fiercely competitive market.

UPDATE 2-Novo, Sanofi go head to head as FDA clears new diabetes drugs

* Companies to sell two-drug products at discount (Adds detail on pricing, quote from Novo Nordisk executive)

BRIEF-Sanofi sees Soliqua costing about same as a GLP-1 drug in U.S.

* Says expects daily wholesale acquisition cost of new diabetes drug Soliqua will be similar to daily price of a GLP-1 in U.S.

No early win for Sanofi, Regeneron cholesterol drug in study

Sanofi and Regeneron Pharmaceuticals said on Thursday they would continue a large clinical outcomes study with their injectable cholesterol-lowering drug Praluent, confounding hopes of some investors for an early win.

UPDATE 1-No early win for Sanofi, Regeneron cholesterol drug in study

Nov 17 Sanofi and Regeneron Pharmaceuticals said on Thursday they would continue a large clinical outcomes study with their injectable cholesterol-lowering drug Praluent, confounding hopes of some investors for an early win.

No early win for Sanofi, Regeneron cholesterol drug in study

Nov 17 Sanofi and Regeneron Pharmaceuticals said on Thursday they would continue a large clinical outcomes study with their injectable cholesterol-lowering drug Praluent.

France sets up fund for Sanofi epilepsy drug victims

PARIS France is setting up a fund to meet compensation claims from people affected by an epilepsy treatment made by Sanofi that is believed to cause birth malfunctions and slow neurological development.

BRIEF-Regeneron and Sanofi Present Results from late-stage Monarch study at American College of Rheumatology Annual Meeting

* Regeneron Pharmaceuticals-In MONARCH study, sarilumab monotherapy showed superiority over adalimumab monotherapy in adults with active rheumatoid arthritis

Select another date: